CANCER:

Brain Cancer

Related cancers:

‹

CNS Tumor (351)

Medulloblastoma (26)

CNS Tumor (351)

Medulloblastoma (26)

›

IDH1 mutation + WT1 overexpression IDH1 mutation + WT1 overexpression	Glioblastoma GBM	temozolomide Sensitive: C3 – Early Trials Biologics - 1 week
JARID2 overexpression JARID2 overexpression	Glioma Glioma	temozolomide Sensitive: D – Preclinical Cancer Biol Ther - 3 weeks
No biomarker No biomarker	Glioblastoma GBM	Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Brain Cancer Brain Cancer	lomustine Sensitive: A1 - Approval
No biomarker No biomarker	Astrocytoma Astrocytoma	everolimus Sensitive: A1 - Approval
No biomarker No biomarker	Astrocytoma Astrocytoma	carmustine Sensitive: A1 - Approval
No biomarker No biomarker	Ependymoma Ependymoma	carmustine Sensitive: A1 - Approval
No biomarker No biomarker	Medulloblastoma Medulloblastoma	carmustine Sensitive: A1 - Approval
No biomarker No biomarker	Anaplastic Astrocytoma Anaplastic Astrocytoma	temozolomide Sensitive: A1 - Approval
No biomarker No biomarker	Glioblastoma GBM	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Glioma Glioma	carmustine Sensitive: A1 - Approval
No biomarker No biomarker	Glioblastoma GBM	temozolomide Sensitive: A1 - Approval
No biomarker No biomarker	Glioblastoma GBM	carmustine Sensitive: A1 - Approval
No biomarker No biomarker	Glioblastoma GBM	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Glioblastoma GBM	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Glioblastoma GBM	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Glioma Glioma	DS-1647 Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Glioblastoma GBM	trametinib + dabrafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Glioblastoma GBM	PCV Sensitive: A2 - Guideline
No biomarker No biomarker	Anaplastic Astrocytoma Anaplastic Astrocytoma	PCV Sensitive: A2 - Guideline
No biomarker No biomarker	Glioma Glioma	PCV Sensitive: A2 - Guideline
MGMT promoter methylation MGMT promoter methylation	Glioblastoma GBM	temozolomide Sensitive: A2 - Guideline
No biomarker No biomarker	Oligodendroglioma Oligodendroglioma	temozolomide Sensitive: A2 - Guideline
No biomarker No biomarker	Glioma Glioma	temozolomide Sensitive: A2 - Guideline
No biomarker No biomarker	Meningioma Meningioma	bevacizumab + everolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Meningioma Meningioma	bevacizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Meningioma Meningioma	sunitinib Sensitive: A2 - Guideline
No biomarker No biomarker	Medulloblastoma Medulloblastoma	cisplatin + cyclophosphamide oral + vincristine Sensitive: A2 - Guideline
No biomarker No biomarker	Medulloblastoma Medulloblastoma	cisplatin + vincristine + lomustine Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	trametinib + dabrafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Glioma Glioma	bevacizumab Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	vemurafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	trametinib + dabrafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Astrocytoma Astrocytoma	lomustine + procarbazine hydrochloride + vincristine liposomal Sensitive: A2 - Guideline
No biomarker No biomarker	Glioblastoma GBM	lomustine Sensitive: A2 - Guideline
No biomarker No biomarker	Glioblastoma GBM	regorafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	vemurafenib + cobimetinib Sensitive: A2 - Guideline
No biomarker No biomarker	Astrocytoma Astrocytoma	temozolomide gel Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Glioma Glioma	selumetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	vemurafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	trametinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Astrocytoma Astrocytoma	dabrafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	cobimetinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	trametinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Ganglioglioma Ganglioglioma	dabrafenib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Glioma Glioma	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Glioma Glioma	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Glioma Glioma	larotrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Glioma Glioma	lomustine Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Glioma Glioma	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Glioma Glioma	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Glioma Glioma	entrectinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Glioblastoma GBM	vemurafenib + cobimetinib Sensitive: A2 - Guideline
BRAF fusion BRAF fusion	Glioma Glioma	selumetinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Glioblastoma GBM	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Glioblastoma GBM	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Glioblastoma GBM	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Glioblastoma GBM	larotrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Glioblastoma GBM	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Glioblastoma GBM	entrectinib Sensitive: A2 - Guideline
No biomarker No biomarker	Ependymoma Ependymoma	lomustine Sensitive: A2 - Guideline
No biomarker No biomarker	Ependymoma Ependymoma	etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Glioma Glioma	etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Medulloblastoma Medulloblastoma	cyclophosphamide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Ependymoma Ependymoma	lapatinib Sensitive: A2 - Guideline
No biomarker No biomarker	Ependymoma Ependymoma	temozolomide Sensitive: A2 - Guideline
No biomarker No biomarker	Ependymoma Ependymoma	bevacizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Meningioma Meningioma	DG3173 Sensitive: A2 - Guideline
No biomarker No biomarker	Medulloblastoma Medulloblastoma	vismodegib Sensitive: A2 - Guideline
No biomarker No biomarker	Medulloblastoma Medulloblastoma	cisplatin + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Medulloblastoma Medulloblastoma	etoposide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Medulloblastoma Medulloblastoma	temozolomide Sensitive: A2 - Guideline
No biomarker No biomarker	Medulloblastoma Medulloblastoma	cyclophosphamide oral + etoposide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Medulloblastoma Medulloblastoma	carboplatin + cyclophosphamide oral + etoposide oral Sensitive: A2 - Guideline
No biomarker No biomarker	Glioblastoma GBM	VAL-083 Sensitive: B - Late Trials
No biomarker No biomarker	Glioblastoma GBM	enzastaurin Sensitive: B - Late Trials
No biomarker No biomarker	Glioblastoma GBM	DNX-2401 Sensitive: B - Late Trials
H3.3K27M H3.3K27M	Glioma Glioma	ONC201 Sensitive: B - Late Trials
No biomarker No biomarker	Glioblastoma GBM	GDC-0084 Sensitive: B - Late Trials
MGMT unmethylation MGMT unmethylation	Glioblastoma GBM	temozolomide Sensitive: B - Late Trials
IDH1 mutation IDH1 mutation	Glioma Glioma	temozolomide gel Sensitive: B - Late Trials
IDH1 R132H IDH1 R132H	Anaplastic Astrocytoma Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	temozolomide Sensitive: B - Late Trials
IDH1 mutation IDH1 mutation	Glioma Glioma	temozolomide Sensitive: B - Late Trials
MGMT promoter methylation MGMT promoter methylation	Anaplastic Astrocytoma Anaplastic Astrocytoma	temozolomide Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	temozolomide gel Sensitive: B - Late Trials
IDH1 mutation IDH1 mutation	Glioma Glioma	PCV Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	PCV Sensitive: B - Late Trials
No biomarker No biomarker	Glioblastoma GBM	GLR2007 Sensitive: B - Late Trials
No biomarker No biomarker	Glioblastoma GBM	VB-111 Sensitive: B - Late Trials
No biomarker No biomarker	Glioma Glioma	OKN-007 Sensitive: B - Late Trials
No biomarker No biomarker	Glioblastoma GBM	CYNK-001 Sensitive: B - Late Trials

Brain Cancer

Associations(347)

Associations
(347)